Recommended methods for determining responsiveness and minimally important differences for patient-reported outcomes.

[1]  Jacob Cohen.  Statistical Power Analysis for the Behavioral Sciences , 1969, The SAGE Encyclopedia of Research Design.

[2]  G. Guyatt,et al.  Measuring change over time: assessing the usefulness of evaluative instruments. , 1987, Journal of chronic diseases.

[3]  Lewis E. Kazis,et al.  Effect Sizes for Interpreting Changes in Health Status , 1989, Medical care.

[4]  G. Guyatt,et al.  Measurement of health status. Ascertaining the minimal clinically important difference. , 1989, Controlled clinical trials.

[5]  M. Liang,et al.  Comparisons of Five Health Status Instruments for Orthopedic Evaluation , 1990, Medical care.

[6]  N. Jacobson,et al.  Clinical significance: a statistical approach to defining meaningful change in psychotherapy research. , 1991, Journal of consulting and clinical psychology.

[7]  D. Osoba,et al.  Letters to the editor: Assessing quality of life in clinical trials , 1993 .

[8]  G H Guyatt,et al.  Determining a minimal important change in a disease-specific Quality of Life Questionnaire. , 1994, Journal of clinical epidemiology.

[9]  Seymour Sudman,et al.  Autobiographical memory and the validity of retrospective reports , 1994 .

[10]  M H Liang,et al.  Evaluating measurement responsiveness. , 1995, The Journal of rheumatology.

[11]  A R Nissenson,et al.  The effects of recombinant human erythropoietin on functional health and well-being in chronic dialysis patients. , 1996, Journal of the American Society of Nephrology : JASN.

[12]  Ron D. Hays,et al.  Quality of life assessment in clinical trials : methods and practice , 1998 .

[13]  D. Osoba,et al.  Interpreting the significance of changes in health-related quality-of-life scores. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  D A Revicki,et al.  Recommendations for evaluating the validity of quality of life claims for labeling and promotion. , 1999, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[15]  W. Tierney,et al.  Further evidence supporting an SEM-based criterion for identifying meaningful intra-individual changes in health-related quality of life. , 1999, Journal of clinical epidemiology.

[16]  W M Tierney,et al.  Linking clinical relevance and statistical significance in evaluating intra-individual changes in health-related quality of life. , 1999, Medical care.

[17]  P. Fayers,et al.  Quality of Life: Assessment, Analysis, and Interpretation , 2000 .

[18]  J. Ware,et al.  Determining minimally important changes in generic and disease-specific health-related quality of life questionnaires in clinical trials of rheumatoid arthritis. , 2000, Arthritis and rheumatism.

[19]  C. Bombardier,et al.  Looking for important change/differences in studies of responsiveness. OMERACT MCID Working Group. Outcome Measures in Rheumatology. Minimal Clinically Important Difference. , 2001, The Journal of rheumatology.

[20]  Gordon H Guyatt,et al.  Methods to explain the clinical significance of health status measures. , 2002, Mayo Clinic proceedings.

[21]  D. Cella,et al.  Combining anchor and distribution-based methods to derive minimal clinically important differences on the Functional Assessment of Cancer Therapy (FACT) anemia and fatigue scales. , 2002, Journal of pain and symptom management.

[22]  P. Jones.  Interpreting thresholds for a clinically significant change in health status in asthma and COPD , 2002, European Respiratory Journal.

[23]  D. Cella,et al.  Group vs individual approaches to understanding the clinical significance of differences or changes in quality of life. , 2002, Mayo Clinic proceedings.

[24]  D. Patrick,et al.  Assessing meaningful change in quality of life over time: a users' guide for clinicians. , 2002, Mayo Clinic proceedings.

[25]  J. Brazier,et al.  What is the relationship between the minimally important difference and health state utility values? The case of the SF-6D , 2003, Health and quality of life outcomes.

[26]  Ross D Crosby,et al.  Defining clinically meaningful change in health-related quality of life. , 2003, Journal of clinical epidemiology.

[27]  A guide for clinicians to compare the accuracy and precision of health-related quality-of-life data relative to other clinical measures , 2003 .

[28]  G. Norman,et al.  Interpretation of Changes in Health-related Quality of Life: The Remarkable Universality of Half a Standard Deviation , 2003, Medical care.

[29]  B. Fridley,et al.  Practical Guidelines for Assessing the Clinical Significance of Health-Related Quality of Life Changes within Clinical Trials , 2003 .

[30]  R. Willke,et al.  Measuring treatment impact: a review of patient-reported outcomes and other efficacy endpoints in approved product labels. , 2004, Controlled clinical trials.

[31]  I. Barofsky,et al.  Recommendations on health-related quality of life research to support labeling and promotional claims in the United States , 2004, Quality of Life Research.

[32]  C. Gotay,et al.  Outcomes assessment in cancer : measures, methods, and applications , 2004 .

[33]  D. Cella,et al.  Meaningful change in cancer-specific quality of life scores: Differences between improvement and worsening , 2002, Quality of Life Research.

[34]  J. Sloan,et al.  Issues for Statisticians in Conducting Analyses and Translating Results for Quality of Life End Points in Clinical Trials , 2004, Journal of biopharmaceutical statistics.

[35]  D. Osoba,et al.  The clinical value and meaning of health-related quality-of-life outcomes in oncology , 2004 .

[36]  R. Epstein,et al.  Interpretation of quality of life changes , 1993, Quality of Life Research.

[37]  R. Hays,et al.  Estimating clinically significant differences in quality of life outcomes , 2004, Quality of Life Research.

[38]  R. Hays,et al.  Responsiveness to change: an aspect of validity, not a separate dimension , 1992, Quality of Life Research.

[39]  D. Cella,et al.  Minimally important differences were estimated for the Functional Assessment of Cancer Therapy-Colorectal (FACT-C) instrument using a combination of distribution- and anchor-based approaches. , 2005, Journal of clinical epidemiology.

[40]  R. Hays,et al.  Clinical significance of patient-reported questionnaire data: another step toward consensus. , 2005, Journal of clinical epidemiology.

[41]  Ron D Hays,et al.  Evaluating the Statistical Significance of Health-Related Quality-Of-Life Change in Individual Patients , 2005, Evaluation & the health professions.

[42]  J. Sloan.  Assessing the Minimally Clinically Significant Difference: Scientific Considerations, Challenges and Solutions , 2005, COPD.

[43]  D. Eton,et al.  Combining Distribution- and Anchor-Based Approaches to Determine Minimally Important Differences , 2005, Evaluation & the health professions.

[44]  C. Gotay.  Advancing Health Outcomes Research Methods and Clinical Applications , 2006, Quality of Life Research.

[45]  D. Revicki,et al.  Impact of omalizumab on quality-of-life outcomes in patients with moderate-to-severe allergic asthma. , 2006, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.

[46]  N. Santanello,et al.  Interpreting and reporting results based on patient-reported outcomes. , 2007, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.